CLOs on the Move

Aquinox Pharmaceuticals

www.aqxpharma.com

 
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox`s lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.aqxpharma.com
  • Suite 450 – 887 Great Northern Way
    Vancouver, BC CAN V5T 4T5
  • Phone: 604.629.9223

Executives

Name Title Contact Details

Similar Companies

Q Therapeutics

Q Therapeutics is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Concuity

Concuity is a Vernon Hills, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Benitec Ltd

Benitec is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference (RNAi) with gene therapy with a goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration.

Translate Bio

Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. Our proprietary mRNA therapeutic platform (MRTTM) is designed to develop product candidates that deliver mRNA carrying instructions to produce intracellular, transmembrane and secreted proteins for therapeutic benefit. We believe that our MRTTM platform is applicable to a broad range of diseases caused by insufficient protein production or where production of proteins can modify disease, including diseases that affect the lung, liver, eye, central nervous system, lymphatic system and circulatory system. Our two lead programs are being developed as treatments for cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency.